3 / 5 Stars
5 5 2 1 5
Zacks Investment Research
5 (Strong Sell)
Standard & Poor's
3 / 5 Stars
#20 in Health
U.S. News evaluated 33 Health Funds. Our list highlights the top-rated funds for long-term investors based on the ratings of leading fund industry researchers.
The fund has returned 40.34 percent over the past year, 31.24 percent over the past three years, 26.65 percent over the past five years, and 13.35 percent over the past decade.
|Trailing Returns||Updated 06.30.2014|
|Year to date||13.3%|
|3 Years (Annualized)||31.2%|
|5 Years (Annualized)||26.6%|
|10 Years (Annualized)||13.4%|
The investment seeks to provide capital appreciation. Under normal circumstances, the fund invests substantially all (at least 80%) of its net assets in equity securities of Biotechnology Companies that are traded in the United States and in derivatives, which primarily consist of futures contracts and options on securities, futures contracts, and stock indices. It will invest to a significant extent in the securities of Biotechnology Companies that have small to mid-sized capitalizations. The fund is non-diversified.
Fees are Low compared to funds in the same category.
Rydex Series Trust Biotechnology Fund has an expense ratio of 1.61 percent.
Risk is High compared to funds in the same category according to Morningstar.